U.S. markets open in 9 hours 9 minutes
  • S&P Futures

    4,608.25
    +18.25 (+0.40%)
     
  • Dow Futures

    35,362.00
    +150.00 (+0.43%)
     
  • Nasdaq Futures

    15,898.50
    +55.75 (+0.35%)
     
  • Russell 2000 Futures

    2,216.70
    +13.10 (+0.59%)
     
  • Crude Oil

    70.24
    +0.75 (+1.08%)
     
  • Gold

    1,778.10
    -1.40 (-0.08%)
     
  • Silver

    22.32
    +0.05 (+0.23%)
     
  • EUR/USD

    1.1292
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.4340
    +0.0910 (+6.78%)
     
  • Vix

    27.18
    -3.49 (-11.38%)
     
  • GBP/USD

    1.3289
    +0.0028 (+0.21%)
     
  • USD/JPY

    113.6750
    +0.1850 (+0.16%)
     
  • BTC-USD

    51,113.20
    +2,096.85 (+4.28%)
     
  • CMC Crypto 200

    1,318.71
    +58.55 (+4.65%)
     
  • FTSE 100

    7,232.28
    +109.96 (+1.54%)
     
  • Nikkei 225

    28,502.43
    +575.06 (+2.06%)
     

Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?

·4 min read
Can Merck's Antiviral for COVID Succeed Where Gilead's Failed?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Earlier this month, Merck (NYSE: MRK) announced it was ending clinical trials of its antiviral pill candidate for treating COVID-19, molnupiravir, on account of the potential therapy's high level of effectiveness. Take Gilead Sciences' (NASDAQ: GILD) antiviral drug, remdesivir. Will Merck's drug follow a similar or better path?